Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Brain Tumor Pathology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10014-017-0277-9PMID 28197780
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

  2014cited by this paper
• IDH1 mutation analysis in low cellularity specimen: a limitation of diagnostic accuracy and a proposal for the diagnostic procedure.

  2013cited by this paper
• Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

  2013cited by this paper
• A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.

  2013cited by this paper
• Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.

  2013cited by this paper
• IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA‐Mediated Clamping PCR

  2013cited by this paper
• What do we know about IDH1/2 mutations so far, and how do we use it?

  2013cited by this paper
• A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy

  2013cited by this paper
• Interlaboratory comparison of IDH mutation detection

  2013cited by this paper
• Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

  2013cited by this paper
• Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

  2012cited by this paper
• Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation

  2012cited by this paper
• IDH1 mutations in grade II astrocytomas are associated with unfavorable progression‐free survival and prolonged postrecurrence survival

  2012cited by this paper
• Pyrosequencing of IDH1 and IDH2 Mutations in Brain Tumors and Non-neoplastic Conditions

  2012cited by this paper
• The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations

  2011cited by this paper
• A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

  2011cited by this paper
• Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma

  2010cited by this paper
• A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples.

  2010cited by this paper
• Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

  2010cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

  2009cited by this paper
• Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

  2009cited by this paper
• Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

  2009cited by this paper
• A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.

  2009cited by this paper
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

  2009cited by this paper
• Analysis of IDH1 and IDH2 mutations in Japanese glioma patients

  2009cited by this paper
• Monoclonal antibody specific for IDH1 R132H mutation

  2009cited by this paper
• Analysis of the IDH1 codon 132 mutation in brain tumors

  2008cited by this paper
• Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.

  2007cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• The 2007 WHO classification of tumours of the central nervous system

  2007cited by this paper
• Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

  2005cited by this paper
• Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation

  2004cited by this paper
• A Sequencing Method Based on Real-Time Pyrophosphate

  1998cited by this paper

• TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors

  2020cites this paper
• Pathology, Epidemiology, and WHO Classification of Brain Tumors

  2020cites this paper
• Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples

  2020cites this paper
• TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations

  2020cites this paper
• Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

  2019cites this paper
• miR-378a-3p inhibits cellular proliferation and migration in glioblastoma multiforme by targeting tetraspanin 17

  2019cites this paper
• A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations

  2019cites this paper
• Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age

  2019cites this paper
• Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing

  2018cites this paper
• Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.

  2018cites this paper
• Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody

  2018cites this paper
• Machine learning: a useful radiological adjunct in determination of a newly diagnosed glioma’s grade and IDH status

  2018cites this paper
• Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted

  2018cites this paper
• Frequent false‐negative immunohistochemical staining with IDH1 (R132H)‐specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis

  2018cites this paper
• Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny.

  2018cites this paper
• Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors

  2018cites this paper
• Long non-coding RNA PAR5 inhibits the proliferation and progression of glioma through interaction with EZH2.

  2017cites this paper
• How to understand the Results of Basic Glioma Genome Sequence Data

  2017cites this paper
• The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision

  2017cites this paper
• Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data

  2016cites this paper
• A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

  2016cites this paper
• Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma

  2016cites this paper
• Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.

  2016cites this paper
• Immunohistochemical profiles of IDH1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas

  2015cites this paper
• Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas

  2015cites this paper
• A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.

  2015cites this paper
• Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers

  2015cites this paper
• A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.

  2015cites this paper